Familial hypertrophic cardiomyopathy (HCM) is an inheritable autosomal dominant trait, displaying abnormal thickening of myocardium and histologic manifestations. To date, considerable studies have uncovered the correlation between gene mutations and HCM. However, the underlying developmental etiology remains largely unknown due to the limited access to obtain cardiomyocytes (CMs) from patients with this disease. Recent breakthrough in generation of human induced pluripotent stem cells (iPSCs) from skin or blood and de novo differentiation into cardiomyocytes (iPSC-CMs) offers a novel source for disease modeling. Using this strategy, we have a unique opportunity to study the developmental etiology of HCM. This proposal will demonstrate the feasibility of elucidating myofilament diseases with patient-specific iPSC-CMs and genome-edited iPSC-CMs.
Aim 1 is to generate iPSCs from patients with HCM mutations and matched family controls as well as unrelated healthy donors.
Aim 2 is to determine the extent of disease by performing molecular and functional analyses of iPSC-CMs.
Aim 3 is to recapitulate sarcomeric HCM disease phenotype with genome editing technology. In summary, we believe findings from this study will yield novel insights into our understanding of the developmental etiology of HCM and give rise to potential new targets for therapeutic strategy of HCM.

Public Health Relevance

Familial hypertrophic cardiomyopathy (HCM) is the most commonly inherited cardiovascular disease, affecting 1 in 500 people worldwide with outcomes ranging from reduced quality of life to sudden cardiac death (SCD). Although surgical reduction of hypertrophic heart (e.g., myomectomy) can improve clinical symptoms and implantable defibrillator can prevent SCD, no specific pharmacological therapy is currently available to cure HCM. To date, the majority of HCM studies have been performed in cell lines and animal models. Due to physiological differences between animals and humans, as well as the secondary abnormalities resulting from end-stage HCM, these studies provided only limited understanding of the underlying mechanism of HCM disease phenotype. Using a multi-disciplinary approach, we will provide novel mechanistic insights into the pathological processes of sarcomeric HCM by deriving patient-specific iPSCs and genome-edited iPSCs to recapitulate the disease process and understand its mechanism of progression.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL126527-04
Application #
9417960
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Desvigne-Nickens, Patrice
Project Start
2015-03-10
Project End
2019-01-31
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Seeger, Timon; Porteus, Matthew; Wu, Joseph C (2017) Genome Editing in Cardiovascular Biology. Circ Res 120:778-780
Zhao, Ming-Tao; Shao, Ning-Yi; Hu, Shijun et al. (2017) Cell Type-Specific Chromatin Signatures Underline Regulatory DNA Elements in Human Induced Pluripotent Stem Cells and Somatic Cells. Circ Res 121:1237-1250
Karakikes, Ioannis; Termglinchan, Vittavat; Cepeda, Diana A et al. (2017) A Comprehensive TALEN-Based Knockout Library for Generating Human-Induced Pluripotent Stem Cell-Based Models for Cardiovascular Diseases. Circ Res 120:1561-1571
Li, Yingxin; Sallam, Karim; Schwartz, Peter J et al. (2017) Patient-Specific Induced Pluripotent Stem Cell-Based Disease Model for Pathogenesis Studies and Clinical Pharmacotherapy. Circ Arrhythm Electrophysiol 10:
Zhao, Ming-Tao; Chen, Haodong; Liu, Qing et al. (2017) Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. Proc Natl Acad Sci U S A 114:E11111-E11120
Shukla, Praveen; Wu, Joseph C (2017) Cardiac subtype characterization using all-optical action potential imaging. Eur Heart J 38:302-304
Sayed, Nazish; Liu, Chun; Wu, Joseph C (2016) Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol 67:2161-2176
Chanana, Anita M; Rhee, June-Wha; Wu, Joseph C (2016) Human-induced pluripotent stem cell approaches to model inborn and acquired metabolic heart diseases. Curr Opin Cardiol 31:266-74
Liang, Ping; Sallam, Karim; Wu, Haodi et al. (2016) Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome. J Am Coll Cardiol 68:2086-2096
Chen, Ian Y; Matsa, Elena; Wu, Joseph C (2016) Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol 13:333-49

Showing the most recent 10 out of 22 publications